Fig. 2: Trp53 loss results in mixed responses and therapy resistance in murine models of NSCLC. | Nature Communications

Fig. 2: Trp53 loss results in mixed responses and therapy resistance in murine models of NSCLC.

From: Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Fig. 2

a Mouse-to-human across genome synteny histograms. Upper panel E mice vs. patients with E tumors. Lower panel EP mice vs patients with EP tumors. Significantly changed regions in both species are colored pink (gain) and blue (loss). b Kaplan–Meier survival analysis of E (n = 10, yellow line) and EP (n = 17, green line) mice, demonstrating the difference in OS after erlotinib treatment (p < 0.0001, HR 3.72, 95% CI: 1.65–8.38, log-rank Mantel–Cox test). c Differences in tumor responses after one month of erlotinib treatment in E (n = 12 yellow) and EP (n = 16 green) mice, presented as % change in CT-measured tumor diameter. Each column represents one mouse, and each dot represents one tumor within the mouse (p = 0.006464, two-sided Mann–Whitney U-test). The dotted lines show the Reiter et al criteria for response (−30%) and progression (10%), respectively. d Bar chart showing the proportion of sensitive and resistant tumors in E (yellow) and EP (green) mice (p = 0.0082, two-sided chi-squared test). The total number of mice in each group are indicated in the bars. e Dot plot showing time to resistance in E (n = 13 yellow) and EP (n = 18 green) mice (P = <0.0001 two-sided Mann–Whitney U-test). f Bar chart showing identified single-nucleotide variant-related resistance mechanisms in E and EP mice. Source data are provided as a Source Data file.

Back to article page